<p>在这一周，尽管面临通胀压力和地缘政治不确定性，全球市场在稳健的企业盈利和标准普尔 500 指数及纳斯达克综合指数创下历史新高的背景下展现出韧性。随着投资者在这些动态条件中进行导航，识别与有利经济指标相符的高增长科技股可能是把握这一不断演变的市场潜在机会的关键。</p>
<h3>全球十大高增长科技公司</h3>
<table>
<thead>
<tr>
<th>名称</th>
<th>收入增长</th>
<th>盈利增长</th>
<th>增长评级</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intellego Technologies</td>
<td>28.42%</td>
<td>47.04%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Gold Circuit Electronics</td>
<td>20.76%</td>
<td>25.89%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>上海华测导航科技</td>
<td>24.51%</td>
<td>23.48%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Pharma Mar</td>
<td>26.67%</td>
<td>43.29%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>eWeLLLtd</td>
<td>24.95%</td>
<td>24.40%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>KebNi</td>
<td>20.56%</td>
<td>94.46%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Global Security Experts</td>
<td>20.56%</td>
<td>28.04%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CARsgen Therapeutics Holdings</td>
<td>81.53%</td>
<td>96.08%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Elliptic Laboratories</td>
<td>36.33%</td>
<td>78.99%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>JNTC</td>
<td>55.45%</td>
<td>94.52%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们全球高增长科技和人工智能股票筛选器中的 741 只股票的完整列表。</p>
<p>让我们探索筛选结果中的几个突出选项。</p>
<h2>MLOptic (SHSE:688502)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> MLOptic Corp. 是一家精密光学解决方案公司，在中国和国际上运营，市值为 155.5 亿人民币。</p>
<p><strong>运营：</strong> MLOptic Corp. 的主要收入来源于其电子元件与零部件部门，收入为 5.3414 亿人民币。</p>
<p>MLOptic 展现出强劲的财务表现，2025 年第一季度的净收入显著增长，从去年同期的 428 万人民币激增至 1664 万人民币。这一增长得益于年收入增长 22.4%，超过了中国市场整体 12.4% 的增长率。尽管本季度未进行股票回购，但公司在创新方面的战略重点通过其研发投资得以体现，这与其收入增长轨迹相一致，并增强了其在科技领域的竞争优势。该公司维持高质量盈利的能力以及预计年利润增长 30.1% 使其在高增长科技领域中具备持续发展的良好基础。</p>
<ul>
<li>点击探索我们在 MLOptic 健康报告中的详细发现。</li>
<li>查看 MLOptic 的历史表现报告，以了解其过去的表现。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/206c4008-7302-41ed-970c-6a12a218744f/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/206c4008-7302-41ed-970c-6a12a218744f/chart/earnings-and-revenue-growth"/></p>
<p>SHSE:688502 截至 2025 年 7 月的盈利和收入增长</p>
<h2>CASTECH (SZSE:002222)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> CASTECH Inc. 专注于晶体元件、精密光学元件和激光设备的研发、生产和销售，主要在中国，市值为 162.1 亿人民币。</p>
<p><strong>运营：</strong> 该公司的收入主要来自光电行业，收入为 9.0731 亿人民币。</p>
<p>CASTECH 最近被纳入深圳证券交易所的关键指数，标志着市场认可度的提高。这与其强劲的财务表现相一致，年收入增长达到 27.3%，显著超过了中国市场整体 12.4% 的增长率。值得注意的是，盈利年增长率为 34.8%，反映出强大的运营效率和市场需求。公司在研发方面的投入显示出其对创新的承诺，这对于在竞争激烈的科技环境中维持这一势头至关重要。</p>
<ul>
<li>点击这里深入了解 CASTECH 的综合健康报告。</li>
<li>通过查看我们的历史表现报告，获取 CASTECH 的历史表现洞察。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1fdd8182-b577-4de8-8f68-3c95121fc93d/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1fdd8182-b577-4de8-8f68-3c95121fc93d/chart/earnings-and-revenue-growth"/></p>
<p>SZSE:002222 截至 2025 年 7 月的盈利和收入增长</p>
<h2>深圳康泰生物制品 (SZSE:300601)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> 深圳康泰生物制品有限公司专注于疫苗和生物制品的研发、生产和销售，市值为 181.7 亿人民币。</p>
<p><strong>运营：</strong> 康泰生物制品主要通过疫苗和生物制品的销售产生收入。该公司的市值为 181.7 亿人民币。</p>
<p>尽管深圳康泰生物制品在过去一年中面临挑战，盈利增长收缩了 76.1%，但仍预计将出现显著反弹，预计年利润增长为 38.6%。这与其行业平均下降 17.7% 形成鲜明对比。公司的研发投资仍然至关重要，与其战略重点相一致，以推动未来的表现。此外，最近通过股息确认的股东支持反映出对其财务健康和回报投资者价值的信心。</p>
<ul>
<li>解锁我们对深圳康泰生物制品股票分析的全面洞察，查看此健康报告。</li>
<li>通过我们的详细历史表现报告评估深圳康泰生物制品的过去表现。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2cb25d7c-83e3-4062-be32-704c82761ea0/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2cb25d7c-83e3-4062-be32-704c82761ea0/chart/revenue-and-expenses-breakdown"/></p>
<p>SZSE:300601 截至 2025 年 7 月的收入和支出明细</p>
<h2>下一步</h2>
<ul>
<li>深入了解我们识别的 741 只全球高增长科技和人工智能股票。</li>
<li>投资了这些股票中的任何一只？通过 Simply Wall St 简化您的投资组合管理，并随时获取有关您股票的关键更新提醒。</li>
<li>使用 Simply Wall St 应用程序提升您的投资能力，享受跨越每个大洲的市场情报的免费访问。</li>
</ul>
<h2>寻找其他投资？</h2>
<ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>用显示强劲增长潜力的公司来充实您的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
<li>寻找现金流潜力可观但交易价格低于其公允价值的公司。</li>
</ul>
<p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们提供的评论基于历史数据和分析师预测，仅使用无偏见的方法，我们的文章并不旨在提供财务建议。</strong> 它不构成买卖任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>

福晶科技

<p>在强劲的企业盈利和标准普尔 500 指数及纳斯达克创下历史新高的一周，全球市场在通胀和地缘政治不确定性中依然表现出韧性。投资者被鼓励识别高增长的科技股。值得注意的公司包括 MLOptic、福晶科技和深圳康泰生物制品，它们的收入和盈利均显示出显著增长。MLOptic 的收入增长了 22.4%，福晶科技增长了 27.3%，而康泰预计将反弹，利润增长达到 38.6%。文章强调了研发投资和市场认可对科技行业持续增长的重要性</p>

<p>In a week marked by solid corporate earnings and record highs for the S&amp;P 500 and Nasdaq Composite, global markets have shown resilience despite inflationary pressures and geopolitical uncertainties. As investors navigate these dynamic conditions, identifying high-growth tech stocks that align with favorable economic indicators can be key to capitalizing on potential opportunities in this evolving landscape.</p>
<div class="lb-trans"><p>在这一周，尽管面临通胀压力和地缘政治不确定性，全球市场在稳健的企业盈利和标准普尔 500 指数及纳斯达克综合指数创下历史新高的背景下展现出韧性。随着投资者在这些动态条件中进行导航，识别与有利经济指标相符的高增长科技股可能是把握这一不断演变的市场潜在机会的关键。</p>
</div><h3>Top 10 High Growth Tech Companies Globally</h3>
<div class="lb-trans"><h3>全球十大高增长科技公司</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Growth Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intellego Technologies</td>
<td>28.42%</td>
<td>47.04%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Gold Circuit Electronics</td>
<td>20.76%</td>
<td>25.89%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shanghai Huace Navigation Technology</td>
<td>24.51%</td>
<td>23.48%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Pharma Mar</td>
<td>26.67%</td>
<td>43.29%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>eWeLLLtd</td>
<td>24.95%</td>
<td>24.40%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>KebNi</td>
<td>20.56%</td>
<td>94.46%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Global Security Experts</td>
<td>20.56%</td>
<td>28.04%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CARsgen Therapeutics Holdings</td>
<td>81.53%</td>
<td>96.08%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Elliptic Laboratories</td>
<td>36.33%</td>
<td>78.99%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>JNTC</td>
<td>55.45%</td>
<td>94.52%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名称</th>
<th>收入增长</th>
<th>盈利增长</th>
<th>增长评级</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intellego Technologies</td>
<td>28.42%</td>
<td>47.04%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Gold Circuit Electronics</td>
<td>20.76%</td>
<td>25.89%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>上海华测导航科技</td>
<td>24.51%</td>
<td>23.48%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Pharma Mar</td>
<td>26.67%</td>
<td>43.29%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>eWeLLLtd</td>
<td>24.95%</td>
<td>24.40%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>KebNi</td>
<td>20.56%</td>
<td>94.46%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Global Security Experts</td>
<td>20.56%</td>
<td>28.04%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CARsgen Therapeutics Holdings</td>
<td>81.53%</td>
<td>96.08%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Elliptic Laboratories</td>
<td>36.33%</td>
<td>78.99%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>JNTC</td>
<td>55.45%</td>
<td>94.52%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 741 stocks from our Global High Growth Tech and AI Stocks screener.</p>
<div class="lb-trans"><p>点击这里查看我们全球高增长科技和人工智能股票筛选器中的 741 只股票的完整列表。</p>
</div><p>Let's explore several standout options from the results in the screener.</p>
<div class="lb-trans"><p>让我们探索筛选结果中的几个突出选项。</p>
</div><h2>MLOptic (SHSE:688502)</h2>
<div class="lb-trans"><h2>MLOptic (SHSE:688502)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> MLOptic Corp. is a precision optical solutions company that operates both in China and internationally, with a market capitalization of CN¥15.55 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> MLOptic Corp. 是一家精密光学解决方案公司，在中国和国际上运营，市值为 155.5 亿人民币。</p>
</div><p><strong>Operations:</strong> MLOptic Corp.'s primary revenue stream is from its Electronic Components &amp; Parts segment, generating CN¥534.14 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> MLOptic Corp. 的主要收入来源于其电子元件与零部件部门，收入为 5.3414 亿人民币。</p>
</div><p>MLOptic has demonstrated robust financial performance, with a notable increase in Q1 2025 earnings, where net income surged to CNY 16.64 million from CNY 4.28 million year-over-year. This growth is underpinned by a significant annual revenue increase of 22.4%, outpacing the broader Chinese market's growth rate of 12.4%. Despite not engaging in share repurchases this quarter, the company's strategic focus on innovation is evident from its R&amp;D investments, aligning with its revenue growth trajectory and enhancing its competitive edge in the tech sector. The firm’s ability to maintain high-quality earnings and a forecasted annual profit growth of 30.1% positions it well for sustained advancement within the high-growth tech landscape.</p>
<div class="lb-trans"><p>MLOptic 展现出强劲的财务表现，2025 年第一季度的净收入显著增长，从去年同期的 428 万人民币激增至 1664 万人民币。这一增长得益于年收入增长 22.4%，超过了中国市场整体 12.4% 的增长率。尽管本季度未进行股票回购，但公司在创新方面的战略重点通过其研发投资得以体现，这与其收入增长轨迹相一致，并增强了其在科技领域的竞争优势。该公司维持高质量盈利的能力以及预计年利润增长 30.1% 使其在高增长科技领域中具备持续发展的良好基础。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in MLOptic's health report.</li>
<li>Examine MLOptic's past performance report to understand how it has performed in the past.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击探索我们在 MLOptic 健康报告中的详细发现。</li>
<li>查看 MLOptic 的历史表现报告，以了解其过去的表现。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/206c4008-7302-41ed-970c-6a12a218744f/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/206c4008-7302-41ed-970c-6a12a218744f/chart/earnings-and-revenue-growth"/></p>
<p>SHSE:688502 Earnings and Revenue Growth as at Jul 2025</p>
<div class="lb-trans"><p>SHSE:688502 截至 2025 年 7 月的盈利和收入增长</p>
</div><h2>CASTECH (SZSE:002222)</h2>
<div class="lb-trans"><h2>CASTECH (SZSE:002222)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> CASTECH Inc. focuses on the R&amp;D, production, and sale of crystal components, precision optical components, and laser devices primarily in China with a market capitalization of CN¥16.21 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> CASTECH Inc. 专注于晶体元件、精密光学元件和激光设备的研发、生产和销售，主要在中国，市值为 162.1 亿人民币。</p>
</div><p><strong>Operations:</strong> The company derives its revenue primarily from the optoelectronics industry, generating CN¥907.31 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司的收入主要来自光电行业，收入为 9.0731 亿人民币。</p>
</div><p>CASTECH has recently been added to key indices on the Shenzhen Stock Exchange, signaling increased market recognition. This aligns with its robust financial performance, where annual revenue growth stands at 27.3%, significantly outpacing the broader Chinese market's growth rate of 12.4%. Notably, earnings have surged by 34.8% annually, reflecting strong operational efficiency and market demand. The company's commitment to innovation is evident in its R&amp;D investments which are crucial for sustaining this momentum in a competitive tech landscape.</p>
<div class="lb-trans"><p>CASTECH 最近被纳入深圳证券交易所的关键指数，标志着市场认可度的提高。这与其强劲的财务表现相一致，年收入增长达到 27.3%，显著超过了中国市场整体 12.4% 的增长率。值得注意的是，盈利年增长率为 34.8%，反映出强大的运营效率和市场需求。公司在研发方面的投入显示出其对创新的承诺，这对于在竞争激烈的科技环境中维持这一势头至关重要。</p>
</div><ul>
<li>Navigate through the intricacies of CASTECH with our comprehensive health report here.</li>
<li>Gain insights into CASTECH's historical performance by reviewing our past performance report.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里深入了解 CASTECH 的综合健康报告。</li>
<li>通过查看我们的历史表现报告，获取 CASTECH 的历史表现洞察。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1fdd8182-b577-4de8-8f68-3c95121fc93d/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/1fdd8182-b577-4de8-8f68-3c95121fc93d/chart/earnings-and-revenue-growth"/></p>
<p>SZSE:002222 Earnings and Revenue Growth as at Jul 2025</p>
<div class="lb-trans"><p>SZSE:002222 截至 2025 年 7 月的盈利和收入增长</p>
</div><h2>Shenzhen Kangtai Biological Products (SZSE:300601)</h2>
<div class="lb-trans"><h2>深圳康泰生物制品 (SZSE:300601)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Shenzhen Kangtai Biological Products Co., Ltd. focuses on the research, development, production, and distribution of vaccines and biological products with a market cap of CN¥18.17 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 深圳康泰生物制品有限公司专注于疫苗和生物制品的研发、生产和销售，市值为 181.7 亿人民币。</p>
</div><p><strong>Operations:</strong> Kangtai Biological Products generates revenue primarily through the sale of vaccines and biological products. The company operates with a market capitalization of CN¥18.17 billion.</p>
<div class="lb-trans"><p><strong>运营：</strong> 康泰生物制品主要通过疫苗和生物制品的销售产生收入。该公司的市值为 181.7 亿人民币。</p>
</div><p>Shenzhen Kangtai Biological Products, despite a challenging year with earnings growth contracting by 76.1%, still forecasts a notable rebound with an expected annual profit growth of 38.6%. This contrasts sharply with its industry's average decline of 17.7%. The company's R&amp;D investments remain pivotal, aligning with its strategic focus on innovation to drive future performance. Additionally, recent shareholder endorsements via dividend affirmations reflect confidence in its financial health and commitment to returning value to investors.</p>
<div class="lb-trans"><p>尽管深圳康泰生物制品在过去一年中面临挑战，盈利增长收缩了 76.1%，但仍预计将出现显著反弹，预计年利润增长为 38.6%。这与其行业平均下降 17.7% 形成鲜明对比。公司的研发投资仍然至关重要，与其战略重点相一致，以推动未来的表现。此外，最近通过股息确认的股东支持反映出对其财务健康和回报投资者价值的信心。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of Shenzhen Kangtai Biological Products stock in this health report.</li>
<li>Assess Shenzhen Kangtai Biological Products' past performance with our detailed historical performance reports.</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁我们对深圳康泰生物制品股票分析的全面洞察，查看此健康报告。</li>
<li>通过我们的详细历史表现报告评估深圳康泰生物制品的过去表现。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2cb25d7c-83e3-4062-be32-704c82761ea0/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/2cb25d7c-83e3-4062-be32-704c82761ea0/chart/revenue-and-expenses-breakdown"/></p>
<p>SZSE:300601 Revenue and Expenses Breakdown as at Jul 2025</p>
<div class="lb-trans"><p>SZSE:300601 截至 2025 年 7 月的收入和支出明细</p>
</div><h2>Next Steps</h2>
<div class="lb-trans"><h2>下一步</h2>
</div><ul>
<li>Dive into all 741 of the Global High Growth Tech and AI Stocks we have identified here.</li>
<li>Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.</li>
<li>Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.</li>
</ul>
<div class="lb-trans"><ul>
<li>深入了解我们识别的 741 只全球高增长科技和人工智能股票。</li>
<li>投资了这些股票中的任何一只？通过 Simply Wall St 简化您的投资组合管理，并随时获取有关您股票的关键更新提醒。</li>
<li>使用 Simply Wall St 应用程序提升您的投资能力，享受跨越每个大洲的市场情报的免费访问。</li>
</ul>
</div><h2>Seeking Other Investments?</h2>
<div class="lb-trans"><h2>寻找其他投资？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>用显示强劲增长潜力的公司来充实您的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
<li>寻找现金流潜力可观但交易价格低于其公允价值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们提供的评论基于历史数据和分析师预测，仅使用无偏见的方法，我们的文章并不旨在提供财务建议。</strong> 它不构成买卖任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div>

探讨全球市场中的三只高增长科技股票